XML 64 R44.htm IDEA: XBRL DOCUMENT
v3.6.0.2

Collaboration and Licensing Agreements - Additional Information (Detail) - USD ($) | 1 Months Ended | 3 Months Ended | 6 Months Ended
--- | --- | --- | ---
Sep. 30, 2015 | May 31, 2014 | Oct. 31, 2012 | Jun. 30, 2015 | Jun. 30, 2016
Revenue Recognition, Multiple-deliverable Arrangements [Line Items] |  |  |  |  |
Payment received on termination and return of rights | $ 0 |  |  |  |
AstraZeneca [Member] |  |  |  |  |
Revenue Recognition, Multiple-deliverable Arrangements [Line Items] |  |  |  |  |
Upfront payment received |  |  | $ 75,000,000 |  |
Amount of upfront payment for return of licenses |  |  |  | $ 15,000,000 |
Amount of reimbursement paid for certain research and development expenses in consideration of acceleration of transfer of information and materials |  |  |  | 10,000,000 |
Recognized deferred revenue |  |  |  | $ 43,100,000 |
Recognition of licensing and collaborative development revenue |  |  |  |  | $ 0
Sanofi [Member] |  |  |  |  |
Revenue Recognition, Multiple-deliverable Arrangements [Line Items] |  |  |  |  |
Revenue recognized |  | $ 1,250,000 |  |  |

X
- Definition Collaborative arrangement consideration. + References No definition available. + Details
Name: | ardx_CollaborativeArrangementConsideration
Namespace Prefix: | ardx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Collaborative arrangement up front payment. + References No definition available. + Details
Name: | ardx_CollaborativeArrangementUpFrontPayment
Namespace Prefix: | ardx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Payment received on termination of option and license agreement. + References No definition available. + Details
Name: | ardx_PaymentReceivedOnTerminationOfOptionAndLicenseAgreement
Namespace Prefix: | ardx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Recognition of licensing and collaborative development revenue. + References No definition available. + Details
Name: | ardx_RecognitionOfLicensingAndCollaborativeDevelopmentRevenue
Namespace Prefix: | ardx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Revenue from multiple-deliverable arrangements that include licensing fees and services revenue. Licensing revenue is consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity. Services revenue may be derived by providing other, nonspecified, services during the reporting period. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1(d),(e)) -URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688 + Details
Name: | us-gaap_LicenseAndServicesRevenue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Cash received from licensees for license fees during the current period. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 25 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3536-108585 + Details
Name: | us-gaap_ProceedsFromLicenseFeesReceived
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The amount of previously reported deferred or unearned revenue that was recognized as revenue during the period. For cash flows, this element primarily pertains to amortization of deferred credits on long-term arrangements. As a noncash item, it is deducted from net income when calculating cash provided by or used in operations using the indirect method. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 13.A.3) -URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 13.A.4) -URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3602-108585 + Details
Name: | us-gaap_RecognitionOfDeferredRevenue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_CounterpartyNameAxis=ardx_AstraZenecaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_CounterpartyNameAxis=ardx_SanofiMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |